Homology Medicines Past Performance
How has Homology Medicines performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FIXX is currently unprofitable.
Growing Profit Margin: FIXX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FIXX is unprofitable, but has reduced losses over the past 5 years at a rate of 0.6% per year.
Accelerating Growth: Unable to compare FIXX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FIXX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: FIXX has a negative Return on Equity (-2.05%), as it is currently unprofitable.